deltatrials
Completed NA NCT00602407

Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions

A Single Dose, Randomized, Two-Period, Two-Treatment, Crossover Bioequivalency Study of Cilostazol 50 mg Tablets Under Fasting Conditions

Sponsor: Roxane Laboratories

Conditions Intermittent Claudication
Interventions Cilostazol
Updated 6 times since 2017 Last updated: Jan 19, 2018 Started: Feb 29, 2004 Primary completion: Mar 31, 2004 Completion: Mar 31, 2004

A NA clinical study on Intermittent Claudication, this trial is completed. The trial is conducted by Roxane Laboratories and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Feb 2018 — Jun 2018 [monthly]

    Completed NA

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2018 [monthly]

    Completed NA

    First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Roxane Laboratories
Data source: West-Ward Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Austin, United States